Ludwig Center | sciencenewsnet.in

Breaking News

New CWRU study targets suicide risk among LGBTQ+ youth in Cleveland’s child welfare, juvenile justice systems

Architect: Here’s How to Build Homes in Fire-Prone Areas

Study reveals biomarker for high risk of metastasis

BLACK HOLES CAN COOK FOR THEMSELVES, CHANDRA STUDY SHOWS

Weight-Loss Surgery Lowers Risk of Developing Complications of Liver Disease in Patients with Cirrhosis and Obesity

Study Results: Exploring Gastric Cancer Risk Through Oral Microbiomes

Children’s Hospital Los Angeles Adds Transformative Gene Therapy and Expands to 10 Treatments, Becoming the Largest Provider of Pediatric Cell and Gene Therapies on the West Coast

Cancer risk established before birth

For Osteoarthritis Patients, Radiation Can Bring Winter Weather Relief

The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine Selected as a U.S. Site for Neuralink Clinical Trial

28 Jan, 2025

FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation

August 7, 2024 sarah JonasAnnouncement

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 genetic discovery made at the Johns Hopkins Kimmel Cancer Center.

Cancer Immunotherapy Approach Targets Common Genetic Alteration

March 15, 2021 sarah JonasResearch Results

Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response against cells that are missing one gene copy, called loss of heterozygosity (LOH), was developed by researchers at the Ludwig Center, Lustgarten Laboratory and the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center.